Advanced Cell Technology, Inc. · Worcester, MA United States (OTC: ACTC)
| 381 Plantation St. | Phone: 508-756-1212 |
| Worcester, MA | |
| 01605 | |
| United States | 
Map This Company |
Advanced Cell Technology, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
No need to choose between embryonic and adult stem cells -- Advanced Cell Technology (ACT) works with both to develop cellular therapies designed to regenerate human tissue. The company has developed three product platforms based on stem-cell technology. They are retinal pigment epithelial therapy (RPE) for the treatment of degenerative retinal disease; myoblast stem cell therapy to treat chronic heart failure and other heart problems; and the hemangioblast platform (HG) for the treatment of blood and cardiovascular diseases. Though the company is focused on bringing the clinical-stage technologies to market, it is also continuing to conduct research for other regenerative medicine treatments.
Advanced Cell Technology, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - OTC: ACTC Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 22 |
Executives
7 executives listed for Advanced Cell Technology, Inc.'s Worcester, MA location.
| Interim Chairman and CEO | Gary Rabin | |
|---|---|---|
| Chief Scientific Officer | Robert Lanza | |
| Director | Alan Shapiro |